Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic therapy or both.~* Have not had thienopyridine therapy for at least 30 days before the study.~* Are of legal age (at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent.~* For women of child-bearing potential only test negative for pregnancy at the time of enrollment.~Exclusion Criteria:~* Have a defined need for thienopyridine therapy.~* Subjects within ≤30 days of coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).~* Known glycosylated hemoglobin (HbA1c) ≥10 mg/dL within last 3 months prior to study entry.~* Have received fibrinolytic therapy \<48 hours prior to randomization.~* Have active internal bleeding or history of bleeding diathesis.~* Have clinical findings that are, in the judgment of the investigator, associated with an increased risk of bleeding.~* Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or intracranial neoplasm, arteriovenous malformation, or aneurysm.~* Have an International Normalized Ratio (INR) known to be \>1.5 within 1 week of study entry.~* Have a known platelet count of \<100,000/mm3 within 1 week of study entry.~* Have known anemia (hemoglobin \[Hgb\] \<10 gm/dL) within 1 week of study entry.~* Are receiving or will receive oral anticoagulation or other antiplatelet therapy (other than ASA) that cannot be safely discontinued for the duration of the trial.~* Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be discontinued.~* Have a concomitant medical illness that in the opinion of the investigator may interfere with or prevent completion in this study.~* Have known severe hepatic dysfunction (e.g., cirrhosis or portal hypertension).~* Have a history of intolerance or allergy to ASA or approved thienopyridines (ticlopidine or clopidogrel).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor + Aspirin (Type: EXPERIMENTAL): Loading-dose plus daily-dosing for 5-7 days.
- Clopidogrel + Aspirin (Type: ACTIVE_COMPARATOR): Loading-dose plus daily-dosing for 5-7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).